세계의 펩타이드 항생제 시장 : 산업 규모, 점유율, 동향, 기회, 예측, 유형별, 투여 경로별, 유통 경로별, 지역별, 경쟁별(2020-2030년)
Peptide Antibiotics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Route of Administration, By Distribution Channel, By Region and Competition, 2020-2030F
세계의 펩타이드 항생제 시장은 2024년에 51억 7,000만 달러로 평가되었고, 2030년에는 76억 7,000만 달러에 이를 것으로 예측되며, 예측 기간 동안의 CAGR은 6.79%를 보일 것으로 예측됩니다.
펩타이드 항생제는 항균성을 지닌 아미노산의 짧은 사슬로, 다양한 감염성 질환 치료에 사용됩니다. 기존의 저분자 항생제와 달리 펩타이드 항생제는 더 큰 단백질 유사 분자로 구성되며 막 파괴 또는 박테리아 복제 방해와 같은 다양한 메커니즘을 통해 작동합니다. 다중 표적 접근 방식은 박테리아 내성 가능성을 줄여주며, 이는 항균제 내성이 증가하는 시대에 중요한 이점입니다. 메티실린 내성 황색포도상구균(MRSA)과 같은 감염의 확산, 인구 고령화, 외과 수술 증가, 펩타이드 합성 기술 향상 등이 이러한 약물에 대한 수요 증가에 기여하고 있습니다. 또한 펩타이드 항생제는 스튜어드십 프로그램의 일부와 의료 분야의 예방적 응용 분야에서 점점 더 많이 사용되고 있으며, 현대 감염병 관리에서 그 역할이 확대되고 있습니다.
| 시장 개요 |
| 예측 기간 |
2026-2030년 |
| 시장 규모(2024년) |
51억 7,000만 달러 |
| 시장 규모(2030년) |
76억 7,000만 달러 |
| CAGR(2025-2030년) |
6.79% |
| 급성장 부문 |
주사제 |
| 최대 시장 |
북미 |
시장 성장 촉진요인
펩타이드 합성의 발전
주요 시장 과제
높은 개발 비용
주요 시장 동향
항균 펩타이드(AMP)에 대한 인식 증가
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 목소리
제5장 세계의 펩타이드 항생제 시장 전망
- 시장 규모와 예측
- 시장 점유율 및 예측
- 유형별(비리보솜 합성 펩타이드 항생제, 리보솜 합성 펩타이드 항생제)
- 투여 경로별(주사제, 경구, 국소)
- 유통 경로별(병원 약국, 온라인 약국, 소매 약국)
- 지역별
- 기업별(2024년)
- 시장 맵
제6장 아시아태평양의 펩타이드 항생제 시장 전망
- 시장 규모와 예측
- 시장 점유율 및 예측
- 아시아태평양 : 국가별 분석
제7장 유럽의 펩타이드 항생제 시장 전망
- 시장 규모와 예측
- 시장 점유율 및 예측
- 유럽 : 국가별 분석
제8장 북미의 펩타이드 항생제 시장 전망
- 시장 규모와 예측
- 시장 점유율 및 예측
- 북미 : 국가별 분석
제9장 남미의 펩타이드 항생제 시장 전망
- 시장 규모와 예측
- 시장 점유율 및 예측
- 남미 : 국가별 분석
제10장 중동 및 아프리카의 펩타이드 항생제 시장 전망
- 시장 규모와 예측
- 시장 점유율 및 예측
- 중동 및 아프리카 : 국가별 분석
- 남아프리카
- 사우디아라비아
- 아랍에미리트(UAE)
제11장 시장 역학
제12장 시장 동향과 발전
제13장 세계의 펩타이드 항생제 시장 : SWOT 분석
제14장 Porter's Five Forces 분석
- 업계 내 경쟁
- 신규 진입의 가능성
- 공급자의 힘
- 고객의 힘
- 대체품의 위협
제15장 PESTEL 분석
제16장 경쟁 구도
- Pfizer Inc.
- Merck & Co., Inc.
- AbbVie Inc
- GSK Plc
- Sandoz International GmbH
- Xellia Pharmaceuticals
- AuroMedics Pharma LLC
- The Menarini Group
- Teva Pharmaceutical Industries Ltd.
- Novartis AG
제17장 전략적 제안
제18장 기업 소개와 면책사항
HBR
The Global Peptide Antibiotics Market was valued at USD 5.17 Billion in 2024 and is projected to reach USD 7.67 Billion by 2030, growing at a CAGR of 6.79% during the forecast period. Peptide antibiotics are short chains of amino acids with antimicrobial properties, used in the treatment of various infectious diseases. Unlike traditional small-molecule antibiotics, peptide antibiotics consist of larger, protein-like molecules and operate through diverse mechanisms such as membrane disruption or interference with bacterial replication. Their multi-targeted approach reduces the likelihood of bacterial resistance, a key advantage in an era marked by rising antimicrobial resistance. The growing prevalence of infections like Methicillin-resistant Staphylococcus aureus (MRSA), aging populations, increased surgical procedures, and enhanced peptide synthesis technologies are all contributing to the increased demand for these drugs. Moreover, peptide antibiotics are being increasingly used as part of stewardship programs and in prophylactic applications in healthcare, reinforcing their expanding role in modern infectious disease management.
| Market Overview |
|---|
| Forecast Period | 2026-2030 |
| Market Size 2024 | USD 5.17 Billion |
| Market Size 2030 | USD 7.67 Billion |
| CAGR 2025-2030 | 6.79% |
| Fastest Growing Segment | Injectable |
| Largest Market | North America |
Key Market Drivers
Advancements in Peptide Synthesis
Progress in solid-phase peptide synthesis (SPPS) has significantly enhanced the scalability and efficiency of peptide antibiotic production. Techniques such as the use of Fmoc and Boc protecting groups, multi-segment synthesis, and continuous-flow systems have streamlined complex peptide assembly. Automation has also become prevalent, enabling high-throughput synthesis with precision control. These technological innovations allow for cost-effective and rapid production of complex and stable peptides with enhanced bioactivity. Strategies like native chemical ligation and peptide cyclization further contribute to increased therapeutic efficacy and resistance to enzymatic degradation. Improvements in purification and conjugation methods, as well as the integration of peptides into nanoparticle systems, are expanding the applications of peptide antibiotics in targeted drug delivery and diagnostics, fueling their market expansion.
Key Market Challenges
High Development Costs
The development of peptide antibiotics involves substantial investment across preclinical research, clinical trials, regulatory compliance, and large-scale manufacturing. Early-stage discovery and testing of new peptide candidates demand significant funding for laboratory infrastructure, skilled personnel, and animal studies. Clinical trials-particularly in later stages-incur major costs due to patient recruitment, monitoring, and data collection. Regulatory processes also impose strict requirements for demonstrating safety, efficacy, and quality, further adding to development expenses. Additionally, the cost of peptide production, especially at commercial scale, is elevated due to the complexity of synthesis, quality assurance protocols, and the need for specialized manufacturing equipment. Intellectual property management and ongoing pharmacovigilance activities also contribute to the financial burden, making cost a significant hurdle for widespread adoption.
Key Market Trends
Growing Awareness of Antimicrobial Peptides (AMPs)
Antimicrobial peptides (AMPs) are gaining recognition for their broad-spectrum antimicrobial properties and unique mechanisms of action. Sourced from various organisms, AMPs target a wide range of pathogens and exhibit low resistance development potential. Their dual role in microbial eradication and immune modulation enhances their appeal in infectious disease treatment. The integration of AMPs with traditional antibiotics is being explored to improve therapeutic outcomes and limit resistance. Their application is also expanding into wound care and dermatology due to their healing properties. Increased R&D investment by pharmaceutical companies and a focus on developing AMP-based alternatives to conventional antibiotics reflect the market's shift toward innovative and sustainable antimicrobial solutions.
Key Market Players
- Pfizer Inc.
- Merck & Co., Inc.
- AbbVie Inc
- GSK Plc
- Sandoz International GmbH
- The Menarini Group
- Xellia Pharmaceuticals
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- AuroMedics Pharma LLC
Report Scope:
In this report, the Global Peptide Antibiotics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Peptide Antibiotics Market, By Type:
- Non-Ribosomal Synthesized Peptide Antibiotics
- Ribosomal Synthesized Peptide Antibiotics
Peptide Antibiotics Market, By Route of Administration:
Peptide Antibiotics Market, By Distribution Channel:
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
Peptide Antibiotics Market, By Region:
- North America
- United States
- Canada
- Mexico
- Asia-Pacific
- China
- India
- South Korea
- Australia
- Japan
- Europe
- Germany
- France
- United Kingdom
- Spain
- Italy
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Peptide Antibiotics Market.
Available Customizations:
Global Peptide Antibiotics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
- 1.1. Market Definition
- 1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations
2. Research Methodology
- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations
3. Executive Summary
- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Peptide Antibiotics Market Outlook
- 5.1. Market Size & Forecast
- 5.2. Market Share & Forecast
- 5.2.1. By Type (Non-Ribosomal Synthesized Peptide Antibiotics, Ribosomal Synthesized Peptide Antibiotics)
- 5.2.2. By Route of Administration (Injectable, Oral, Topical)
- 5.2.3. By Distribution Channel (Hospital Pharmacy, Online Pharmacy & Retail Pharmacy)
- 5.2.4. By Region
- 5.2.5. By Company (2024)
- 5.3. Market Map
6. Asia Pacific Peptide Antibiotics Market Outlook
- 6.1. Market Size & Forecast
- 6.2. Market Share & Forecast
- 6.2.1. By Type
- 6.2.2. By Route of Administration
- 6.2.3. By Distribution Channel
- 6.2.4. By Country
- 6.3. Asia Pacific: Country Analysis
- 6.3.1. China Peptide Antibiotics Market Outlook
- 6.3.1.1. Market Size & Forecast
- 6.3.1.2. Market Share & Forecast
- 6.3.1.2.1. By Type
- 6.3.1.2.2. By Route of Administration
- 6.3.1.2.3. By Distribution Channel
- 6.3.2. India Peptide Antibiotics Market Outlook
- 6.3.2.1. Market Size & Forecast
- 6.3.2.2. Market Share & Forecast
- 6.3.2.2.1. By Type
- 6.3.2.2.2. By Route of Administration
- 6.3.2.2.3. By Distribution Channel
- 6.3.3. Australia Peptide Antibiotics Market Outlook
- 6.3.3.1. Market Size & Forecast
- 6.3.3.2. Market Share & Forecast
- 6.3.3.2.1. By Type
- 6.3.3.2.2. By Route of Administration
- 6.3.3.2.3. By Distribution Channel
- 6.3.4. Japan Peptide Antibiotics Market Outlook
- 6.3.4.1. Market Size & Forecast
- 6.3.4.2. Market Share & Forecast
- 6.3.4.2.1. By Type
- 6.3.4.2.2. By Route of Administration
- 6.3.4.2.3. By Distribution Channel
- 6.3.5. South Korea Peptide Antibiotics Market Outlook
- 6.3.5.1. Market Size & Forecast
- 6.3.5.2. Market Share & Forecast
- 6.3.5.2.1. By Type
- 6.3.5.2.2. By Route of Administration
- 6.3.5.2.3. By Distribution Channel
7. Europe Peptide Antibiotics Market Outlook
- 7.1. Market Size & Forecast
- 7.2. Market Share & Forecast
- 7.2.1. By Type
- 7.2.2. By Route of Administration
- 7.2.3. By Distribution Channel
- 7.2.4. By Country
- 7.3. Europe: Country Analysis
- 7.3.1. France Peptide Antibiotics Market Outlook
- 7.3.1.1. Market Size & Forecast
- 7.3.1.2. Market Share & Forecast
- 7.3.1.2.1. By Type
- 7.3.1.2.2. By Route of Administration
- 7.3.1.2.3. By Distribution Channel
- 7.3.2. Germany Peptide Antibiotics Market Outlook
- 7.3.2.1. Market Size & Forecast
- 7.3.2.2. Market Share & Forecast
- 7.3.2.2.1. By Type
- 7.3.2.2.2. By Route of Administration
- 7.3.2.2.3. By Distribution Channel
- 7.3.3. Spain Peptide Antibiotics Market Outlook
- 7.3.3.1. Market Size & Forecast
- 7.3.3.2. Market Share & Forecast
- 7.3.3.2.1. By Type
- 7.3.3.2.2. By Route of Administration
- 7.3.3.2.3. By Distribution Channel
- 7.3.4. Italy Peptide Antibiotics Market Outlook
- 7.3.4.1. Market Size & Forecast
- 7.3.4.2. Market Share & Forecast
- 7.3.4.2.1. By Type
- 7.3.4.2.2. By Route of Administration
- 7.3.4.2.3. By Distribution Channel
- 7.3.5. United Kingdom Peptide Antibiotics Market Outlook
- 7.3.5.1. Market Size & Forecast
- 7.3.5.2. Market Share & Forecast
- 7.3.5.2.1. By Type
- 7.3.5.2.2. By Route of Administration
- 7.3.5.2.3. By Distribution Channel
8. North America Peptide Antibiotics Market Outlook
- 8.1. Market Size & Forecast
- 8.2. Market Share & Forecast
- 8.2.1. By Type
- 8.2.2. By Route of Administration
- 8.2.3. By Distribution Channel
- 8.2.4. By Country
- 8.3. North America: Country Analysis
- 8.3.1. United States Peptide Antibiotics Market Outlook
- 8.3.1.1. Market Size & Forecast
- 8.3.1.2. Market Share & Forecast
- 8.3.1.2.1. By Type
- 8.3.1.2.2. By Route of Administration
- 8.3.1.2.3. By Distribution Channel
- 8.3.2. Mexico Peptide Antibiotics Market Outlook
- 8.3.2.1. Market Size & Forecast
- 8.3.2.2. Market Share & Forecast
- 8.3.2.2.1. By Type
- 8.3.2.2.2. By Route of Administration
- 8.3.2.2.3. By Distribution Channel
- 8.3.3. Canada Peptide Antibiotics Market Outlook
- 8.3.3.1. Market Size & Forecast
- 8.3.3.2. Market Share & Forecast
- 8.3.3.2.1. By Type
- 8.3.3.2.2. By Route of Administration
- 8.3.3.2.3. By Distribution Channel
9. South America Peptide Antibiotics Market Outlook
- 9.1. Market Size & Forecast
- 9.2. Market Share & Forecast
- 9.2.1. By Type
- 9.2.2. By Route of Administration
- 9.2.3. By Distribution Channel
- 9.2.4. By Country
- 9.3. South America: Country Analysis
- 9.3.1. Brazil Peptide Antibiotics Market Outlook
- 9.3.1.1. Market Size & Forecast
- 9.3.1.2. Market Share & Forecast
- 9.3.1.2.1. By Type
- 9.3.1.2.2. By Route of Administration
- 9.3.1.2.3. By Distribution Channel
- 9.3.2. Argentina Peptide Antibiotics Market Outlook
- 9.3.2.1. Market Size & Forecast
- 9.3.2.2. Market Share & Forecast
- 9.3.2.2.1. By Type
- 9.3.2.2.2. By Route of Administration
- 9.3.2.2.3. By Distribution Channel
- 9.3.3. Colombia Peptide Antibiotics Market Outlook
- 9.3.3.1. Market Size & Forecast
- 9.3.3.2. Market Share & Forecast
- 9.3.3.2.1. By Type
- 9.3.3.2.2. By Route of Administration
- 9.3.3.2.3. By Distribution Channel
10. Middle East and Africa Peptide Antibiotics Market Outlook
- 10.1. Market Size & Forecast
- 10.2. Market Share & Forecast
- 10.2.1. By Type
- 10.2.2. By Route of Administration
- 10.2.3. By Distribution Channel
- 10.2.4. By Country
- 10.3. MEA: Country Analysis
- 10.3.1. South Africa Peptide Antibiotics Market Outlook
- 10.3.1.1. Market Size & Forecast
- 10.3.1.2. Market Share & Forecast
- 10.3.1.2.1. By Type
- 10.3.1.2.2. By Route of Administration
- 10.3.1.2.3. By Distribution Channel
- 10.3.2. Saudi Arabia Peptide Antibiotics Market Outlook
- 10.3.2.1. Market Size & Forecast
- 10.3.2.2. Market Share & Forecast
- 10.3.2.2.1. By Type
- 10.3.2.2.2. By Route of Administration
- 10.3.2.2.3. By Distribution Channel
- 10.3.3. UAE Peptide Antibiotics Market Outlook
- 10.3.3.1. Market Size & Forecast
- 10.3.3.2. Market Share & Forecast
- 10.3.3.2.1. By Type
- 10.3.3.2.2. By Route of Administration
- 10.3.3.2.3. By Distribution Channel
11. Market Dynamics
- 11.1. Drivers
- 11.2. Challenges
12. Market Trends & Developments
- 12.1. Recent Developments
- 12.2. Product Launches
- 12.3. Mergers & Acquisitions
13. Global Peptide Antibiotics Market: SWOT Analysis
14. Porter's Five Forces Analysis
- 14.1. Competition in the Industry
- 14.2. Potential of New Entrants
- 14.3. Power of Suppliers
- 14.4. Power of Customers
- 14.5. Threat of Substitute Product
15. PESTLE Analysis
16. Competitive Landscape
- 16.1. Pfizer Inc.
- 16.1.1. Business Overview
- 16.1.2. Company Snapshot
- 16.1.3. Products & Services
- 16.1.4. Financials (In case of listed companies)
- 16.1.5. Recent Developments
- 16.1.6. Key Personnel Details
- 16.1.7. SWOT Analysis
- 16.2. Merck & Co., Inc.
- 16.3. AbbVie Inc
- 16.4. GSK Plc
- 16.5. Sandoz International GmbH
- 16.6. Xellia Pharmaceuticals
- 16.7. AuroMedics Pharma LLC
- 16.8. The Menarini Group
- 16.9. Teva Pharmaceutical Industries Ltd.
- 16.10.Novartis AG
17. Strategic Recommendations
18. About Us & Disclaimer
